Zydus Lifesciences Ltd
Zydus Lifesciences Ltd (ZYDUSLIFE) last traded at ₹1,119, a market capitalisation of ₹1,11,601 crore, on a P/E of 22.9. Over the past 52 weeks the stock has ranged between ₹836 and ₹1,206. Zydus Lifesciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹8,017 crore and net profit of ₹990 crore. Figures are as of 25 Aug 2026 and are not real time.
Zydus Lifesciences Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Zydus Lifesciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹8,017 cr, up 22.0% from ₹6,574 cr a year earlier. Net profit was ₹990 cr, down 34.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,864 | 7,587 | 8,017 |
| Expenses | 3,776 | 3,882 | 4,402 | 4,485 | 4,107 | 5,048 | 5,033 | 6,088 |
| Operating profit | 1,461 | 1,388 | 2,126 | 2,088 | 2,016 | 1,816 | 2,554 | 1,929 |
| OPM % | 28% | 26% | 33% | 32% | 33% | 26% | 34% | 24% |
| Other income | 68 | 57 | -139 | 155 | 75 | 26 | -263 | 88 |
| Interest | 25 | 32 | 77 | 85 | 101 | 130 | 123 | 156 |
| Depreciation | 234 | 229 | 238 | 238 | 302 | 360 | 508 | 555 |
| Profit before tax | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,307 |
| Tax % | 29% | 15% | 25% | 23% | 27% | 29% | 19% | 27% |
| Net profit | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 |
| EPS (₹) | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.42 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Zydus Lifesciences Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 15,102 | 15,265 | 17,237 | 19,547 | 23,242 | 27,148 | 28,592 |
| Operating profit | 3,344 | 3,342 | 3,860 | 5,384 | 7,058 | 8,475 | 8,316 |
| OPM % | 22% | 22% | 22% | 28% | 30% | 31% | 29% |
| Net profit | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 | 5,124 | 4,593 |
| EPS (₹) | 20.84 | 43.83 | 19.37 | 38.36 | 44.97 | 50.09 | 44.94 |
TTM is the trailing twelve months to the most recent quarter.
Zydus Lifesciences Ltd growth and returns
- 10 Years
- 11%
- 5 Years
- 12%
- 3 Years
- 16%
- TTM
- 21%
- 10 Years
- 11%
- 5 Years
- 19%
- 3 Years
- 32%
- TTM
- 5%
- 10 Years
- 11%
- 5 Years
- 15%
- 3 Years
- 21%
- 1 Year
- 8%
- 10 Years
- 20%
- 5 Years
- 21%
- 3 Years
- 21%
- Last Year
- 21%
Zydus Lifesciences Ltd shareholding pattern
Promoters held 75.02% at Jun 2026, broadly unchanged since Jun 2025. FIIs 6.89% and DIIs 11.27%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.98% | 74.98% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.02% |
| FIIs | 7.52% | 7.53% | 7.31% | 7.13% | 7.34% | 7.06% | 6.95% | 6.89% |
| DIIs | 10.59% | 10.61% | 10.95% | 11.09% | 10.86% | 11.08% | 11.20% | 11.27% |
| Government | 0.05% | 0.05% | 0.05% | 0.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 6.85% | 6.85% | 6.69% | 6.74% | 6.81% | 6.86% | 6.86% | 6.83% |
| No. of shareholders | 3,70,863 | 3,65,356 | 3,71,619 | 3,86,127 | 3,96,105 | 4,03,266 | 4,18,314 | 3,99,251 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Zydus Lifesciences Ltd corporate filings
- ESG RatingCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences has provided a disclosure regarding its ESG rating. This is a routine…
Read the full analysis - Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Zydus Lifesciences has filed a routine disclosure in compliance with the SEBI…
Read the full analysis - Investor PresentationCompany Updatemedium impact
Cruxal's analysis: Zydus Lifesciences Limited has released its corporate presentation for an investor…
Read the full analysis - ESG RatingCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences has released an update regarding its ESG rating. The disclosure is a…
Read the full analysis - Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity.Company Updatemedium impact
Cruxal's analysis: Zydus Lifesciences has secured final approval from the USFDA for Ascorbic Acid Injection…
Read the full analysis - Transcript of the post results earnings call held on August 11, 2026Company Updatehigh impact
Cruxal's analysis: Zydus Lifesciences reported consolidated revenues of 8,020 crore, a 22% YoY increase…
Read the full analysis - The management of the Company will meet the investors in Singapore and Hong Kong between August 24, 2026, to August 26, 2026, in the form of a Non-Deal Roadshow (NDR).Company Updatelow impact
Cruxal's analysis: Zydus Lifesciences has announced a Non-Deal Roadshow (NDR) for institutional investors in…
Read the full analysis - Update on Investor ConferenceCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences has issued a routine intimation regarding an upcoming analyst/investor…
Read the full analysis - Newspaper cutting with regard to publication of unaudited financial results for the quarter ended on June 30, 2026, in Financial Express on August 12, 2026.Company Updatehigh impact
Cruxal's analysis: Zydus Lifesciences reported Q1 FY27 consolidated revenue of 8,017 crore, reflecting a…
Read the full analysis - Regulation 44(3) disclosure of AGM 2026AGM/EGMlow impact
Cruxal's analysis: Zydus Lifesciences Limited has released the voting results for its 31st Annual General…
Read the full analysis - Change in DirectorsCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences Limited has formally announced the shareholder approval at its 31st…
Read the full analysis - Scrutinizer''s reportAGM/EGMlow impact
Cruxal's analysis: Zydus Lifesciences Limited has successfully concluded its 31st Annual General Meeting…
Read the full analysis - Outcome of AGMAGM/EGMlow impact
Cruxal's analysis: Zydus Lifesciences Limited has successfully concluded its 31st Annual General Meeting…
Read the full analysis - Audio Link of the Investor Call held on August 11 2026Company Updatelow impact
Cruxal's analysis: Zydus Lifesciences has provided the audio link for the investor conference call conducted…
Read the full analysis - Reporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Zydus Lifesciences has formally disclosed a violation of its Code of Conduct under the…
Read the full analysis - Press ReleaseCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences has filed a press release under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Press ReleaseCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences has submitted a press release under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Investor PresentationCompany Updatehigh impact
Cruxal's analysis: Zydus Lifesciences reported Q1 FY27 revenue of 8,017 crore, reflecting a 22% YoY growth…
Read the full analysis - Unaudited financial results for the quarter ended on June 30, 2026Resulthigh impact
Cruxal's analysis: Zydus Lifesciences Limited reported consolidated revenue from operations of 8,017 crore…
Read the full analysis - Zydus launches REVAHALE, India''s first once-daily nebulised LAMA for COPD.Company Updatelow impact
Cruxal's analysis: Zydus Lifesciences has introduced REVAHALE, a once-daily nebulised Long-Acting Muscarinic…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Zydus Lifesciences Ltd
Cruxal reads every Zydus Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.